| Pharmaceutical Information |
| Drug Name |
Pergolide mesylate |
| Drug ID |
BADD_D01736 |
| Description |
Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. While the use of pergolide in humans is still approved in only some countries, pergolide is mainly used for veterinary purposes. |
| Indications and Usage |
Indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. It was withdrawn from the US and Canadian markets in 2007 due to an increased risk of cardiac valvulopathy. |
| Marketing Status |
approved; investigational; vet_approved; withdrawn |
| ATC Code |
N04BC02 |
| DrugBank ID |
DB01186
|
| KEGG ID |
D00502
|
| MeSH ID |
D010479
|
| PubChem ID |
47812
|
| TTD Drug ID |
D04JCN
|
| NDC Product Code |
38779-1952; 60592-921; 47848-008 |
| UNII |
55B9HQY616
|
| Synonyms |
Pergolide | Pharken | Permax | Celance | Parkotil | LY-127809 | LY127809 | LY-127,809 | LY127,809 | Pergolide Mesylate | Mesylate, Pergolide |
|
| Chemical Information |
| Molecular Formula |
C20H30N2O3S2 |
| CAS Registry Number |
66104-23-2 |
| SMILES |
CCCN1CC(CC2C1CC3=CNC4=CC=CC2=C34)CSC.CS(=O)(=O)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
